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Clinicians make decisions that affect life and death, quality of life, every single day. It is 
important to support clinicians by discovering medical knowledge from the accumulated 
electronic health records (EHRs). The integration of genomic information and EHRs are 
long recognized by the medical community as the inherent feature of the disease. The 
demand for developing a clinical recommender system that is able to deal with both 
genomic and phenotypic data is urgent. This paper proposes a framework of clinical 
recommender system with genomic information, which is used in the clinical process and 
connects the four types of users: clinicians, patients, clinical labs, researchers. With models 
and methods in artificial intelligence (AI), five functions are designed in this framework: 
diagnosis prediction, disease risk prediction, test prediction, and event prediction. The 
proposed framework will help clinicians to make decisions on the next step in clinical care 
action for patients.  
Keywords: Recommender system; Clinical recommender system, Genomic information, 
Precision medicine. 
1.   Introduction 
Due to the large number of patients clinicians are meeting every day, efficiency 
and accuracy of decision making are quite crucial in clinical medicine1. Because 
of the fast variation of diseases, numerous new drugs are developed to deal with 
different situations occurred to patients. It is crucial to keep up to date with plenty 
and complex disease and drug information for clinicians. For example, 
contraindications of many drugs may bring chronic harm to unsuitable patients or 
what’s worse may cause lethal effect. To help clinicians reduce mistakes and 
improve efficiency in making decisions of the next step clinical care action for 
patients, there is a requirement of developing clinical recommender systems.  
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The accumulation of electronic health record (EHR) provides the opportunity 
of building clinical recommender system. EHRs are patient-centered records 
containing demographics, clinician orders, test results, diagnosis, procedures etc. 
in the clinical process2. EHRs provide a multi-view of clinician behavior and 
patient information in clinical process and mainly collected through an EHR 
system. The start of clinical support is by adding smart searching strategies into 
the system. Inforbuttons is a system that allow clinicians to search electronic 
resource collections through queries based on patient data3. Further, a decision 
support system called lung cancer assistant is developed to assist clinicians in 
treatment selection by case-based reasoning and probabilistic models4. 
Disease inheritance has been long recognized by medical community, and 
the genetics is the cause and contributor to the complexity of clinical medicine5. 
If the cause of symptoms is not clearly understood, it is not possible to provide 
the proper treatment to patients. For example, patients are vulnerable of 
developing life-threatening myelosuppression if they harbor genetic variants that 
prevent them from metabolizing the immunosuppressive drug azathioprine 
normally6. The challenge of developing clinical recommender system is how to 
properly deal with the genetic information of patients. Personalized medicine 
(now more widely known as precision medicine) is a term that raised to contain 
the sequencing of human genome in clinical medicine. The link of genomic data 
and EHRs help to understand deeper on the cause and therapies of the diseases7. 
Thus, developing clinical recommender system with genetic information is to use 
genomic approach to tailor the clinical process to prevent the disease and improve 
the healthcare experience of patients. 
To solve the above problems, this study proposes a framework of clinical 
recommender system with genetic information. Firstly, how the clinical 
recommender system framework will work in the clinical process is presented 
from four user perspectives. Then, how genetics helps in the framework on 
predictions of diagnosis, disease risks, test, prescription and other events are 
presented.  
The rest of the paper is arranged as follows. It introduces the related works 
in Section 2. Section 3 explains the clinical process and the framework of clinical 
recommender system. In Section 4, the paper discusses future work and concludes 
this study. 
2.   Related works 
This section demonstrate related work about clinical decision support systems and 
describe how this paper fits into the scope. 
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Clinical decision support “refers broadly to providing clinicians and/or 
patients with clinical knowledge and patient-related information, intelligently 
filtered, or presented at appropriate times, to enhance patient care.”8 The clinical 
decision support can be grouped into three categories: passive, asynchronous and 
active9. Passive decision support refers to non-mandatory resources during the 
clinical process. The EHRs and related system can be seen as an example of 
passive decision support. The easy access to these data to clinicians during the 
consultation and care of the patient provides support for clinicians. Asynchronous 
decision support involves system monitoring, data assembling, report generating 
and email notifications. From the genetic view, some testing such as germline 
genetic test is only needed once in a lifetime. The asynchronous decision support 
system is to monitor and inform clinicians to avoid duplicate testing. The active 
clinical decision support is to provide information such as probability of diagnosis, 
medicines to prescribe and tests to order during the clinical process. One example 
of active clinical decision support is to raise alert when the clinician has given a 
risky decision on prescribing a drug that is allergy for a patient. The study of this 
paper is on the basis of the three types of decision support, and provide 
personalized recommendation for clinicians. 
3.   A Framework of Clinical Recommender System 
This section describes the clinical process overview between the patients, 
clinicians, clinical lab and AI researchers. Followed by the overview of the 
clinical recommender system and the function of each component of the 
framework. 
3.1.   Clinical process: overview and perspectives 
This part gives an overview of how the clinical process goes when a patient comes 
and how the clinical recommender system is involved in this process in Fig. 1.  
When a patient comes to a consultation, the clinician will give the next action 
for the patient, and use the symptoms, test results, family records of the patient to 
help him make the decision. The clinician needs to determine the cause of the 
symptom and patient’s prognosis. To do this, next action such as clinical test or 
genetic test may be needed and all data need to be cooperatively gathered to make 
the final decision. The clinical recommender system is to help clinicians quickly, 
efficiently and accurately predict the most appropriate action for a patient, such 
as order a test, diagnosis, prescription or hospitalization. The aim of the clinical 
recommender system is to simplify the complexity of the clinical process, lower 
the risk of clinician’s decision and managing the information from several sources. 
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Obviously, the process involves four kinds of people that are related to the 
clinical recommender system. We will give four perspective from different users: 
Fig. 1. Clinical process of patient 
(1) Patient perspective: The role of patients is becoming more important 
since they are now able to access their genetic data directly from some testing 
providers. There are more and more concerns on the health privacy and the data 
sharing. So the participate of patient and their consent to access their data are 
crucial for building the clinical recommender system. It is essential to contain a 
portal for patients to make it easier for them to effectively and efficiently consent 
to share their data in supporting research and development of medical health. The 
patient portal is needed in the system to allow patients to visualize their health 
condition, access their full medical data and control their privacy. 
(2) Clinician perspective: The role of clinician is the core part in the whole 
process to give patients suggestion of next step action. Clinicians need to combine 
all the information and interpret the symptom and disease for the patient. The 
interpretation are needed from both phenotypic and genomic side: (1) Phenotypic 
side: Clinicians determine which clinical test might be needed, how the test results 
can reveal the cause and severity of the symptoms and what interventions are 
needed for the patient. (2) Genomic side: Clinicians determine which variants in 
the genome are related to the disease, how the variants affect the symptoms and 
how the variants affect the treatment or clinical care for the patients. The 
interpretation and decision of clinicians contain professional judgement therefore 




































clinical process. The recommender system is truly needed to lower the risk and 
reduce the number of errors by providing personalized recommendation for 
clinicians. 
(3) Clinical lab perspective: The clinical lab provides the results mainly on 
the genomic test, but also the clinical test such as blood test. Clinical labs provide 
all the variants in the genome and their possible relationships with the disease. 
There are many existing variants that are already known with specific impact, but 
more variants are to be discovered and interpreted. The data structure of a 
combination between the clinical test data in EHR database and genomic data in 
genome dataset is needed for the development of the clinical recommender system. 
An example of existing public dataset containing a total of 158,668 variants 
submitted by 369 organizations * is ClinVar from National Center for 
Biotechnology Information (NCBI).  
(4) The AI researcher perspective: Artificial intelligence (AI) is developing 
fast in the era of big data. With both genomic and phenotypic data, there are many 
methods and models to be developed to fit various requirements and provide 
different support to clinicians, or even to medical researchers. The collaboration 
of AI and medicine is needed in establishing gold standard for the relationships 
between phenotypic features such as Prostate cancer and genomic features such 
as single nucleotide polymorphism. Knowledge base should be established as 
basis of building the clinical recommender system, which definitely involves the 
participation of medical experts. Opportunities also lie in the discovery of new 
medical knowledge especially with the genomic information is exploited. 
With incremental data accumulated through each patient consultation and 
interaction, the clinical recommender system is incrementally improved and will 
benefit the clinician, patients, lab and medical researchers. The ultimate goal is to 
give personalized recommendation to support decision making of clinicians and 
improve the healthcare of the patients.  
3.2.   Framework of the clinical recommender system 
This part proposes an overview of the framework of clinical recommender system 
with genomic information as shown in Fig. 2. Since each disease has their specific 
symptoms or features, the clinical recommender systems should be built 
separately on each disease. 
The basis of the clinical recommender system is the preprocessing and 
analysis of the data from both genomic data and phenotypic data respectively: 
 
*  The data is recorded in 11 September 2015. 
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Fig. 2. Framework of clinical recommender system  
(1) Genomic data analysis: As shown in Fig. 2, sequencing data from 
individuals are stored in genome dataset. The genomic data analysis contain two 
levels. The first is the analysis on genetic variations. Genetic variations contain 
two types: single nucleotide polymorphisms (SNPs) and Structural variation (SV). 
Identification of variants connected to specific diseases is the basis of genome 
wide association studies (GWAS). GWAS are methods for identifying 
associations between genetic regions and traits (including diseases). A typical 
GWAS study is to use statistical methods to find the relationship between genetic 
variants and diseases. Except for the level of the gene copy numbers, the gene 
expression level is not only related with disease, but also the sensitivity of drugs. 
GWAS together with gene expression analysis the main component to establish 
the genomic knowledge base. 
(2) Phenotypic data analysis: The main dataset for the phenotypic data is the 
EHR of patients which contains patient demographics, family history, clinician 
orders, diagnoses, procedures, prescriptions, lab test values, hospitalization 
flowsheet and free-text medical notes. Feature selection is needed to extract the 
symptoms and other related features from structured data. Also text mining is 
needed for the unstructured data such as free-text medical notes. With features 
and disease labels, case-level knowledge bases are established. 
 There are five functions in the framework as listed in the right part. Each 
function may be connected with one or more prediction models or methods. Here, 
we briefly introduce one representative method that may achieve the function, and 
emphasis how genetic information plays a part in each function. 
(1) Diagnosis prediction: To make diagnosis, features about symptoms or 
tests are extracted from structured test results or unstructured electrocardiogram. 
Decision tree is able to select features and classify the patients to the appropriate 





















































manifestation. Genetic variants may reveal the cause of disease and provide 
evidence for confirmation of diagnosis. 
(2) Disease risk prediction: This function aims at early disease detection, 
prevention and intervention for asymptomatic individuals. Family history helps 
to show the genetic inheritance of some diseases. Also, genetic variants affect and 
lead to the disease not by single loci but multiple loci. Polygenic score is a number 
from regression analysis on variation in multiple genetic loci with associated 
weights. The utility of polygenic risk profiling is used to predict the probabilistic 
susceptibility of a disease, and patients are classified to high, intermediate and 
low risk to take different actions. Except gene variants, gene expression is also 
highly related with the disease risk. 
(3) Test prediction: The test prediction is mainly on the genetic sequencing 
test. Since the multiple genetic loci are functioning together in many diseases, 
cross-domain regression and recommendation are needed to infer the relationships 
between multiple generic loci. The recommendation results may suggest exome 
sequencing or whole genome sequencing and analysis. Sequencing of parents or 
other family members may also need. 
(4) Prescription prediction: The symptoms, diagnosis and lab test results 
determine the prescription of a clinician to patients. The prescription prediction 
can be solved by case-based reasoning with phenotypic data. Also genetic variants 
and gene expression affect the patient’s respond to drug therapy. Multitask 
learning is effective to deal with complex molecular feature space with multiple 
drugs. 
(5) Event prediction: The EHR can be processed and converted to events 
such as test, therapy or discharge ordered in a timeline. The deep learning method 
especially the attention-based recurrent neural network (RNN) use the time series 
events to make prediction at specific time points. The genetic variants may affect 
mortality and discharge prediction. 
From the above framework, the understanding of genetic variants and gene 
expression can be considered in conjunction with EHR data and support the 
decision making of clinicians on the next step action in various aspects. The 
participation of genetic data in the clinical recommender system is crucial to 
improve the healthcare for the patients. 
4.   Conclusion and future work 
This paper proposes a framework for clinical recommender system to support 
clinicians in decision making for providing patients with better healthcare. How 
the clinical recommender system is working in the clinical process is explained 
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from four user perspectives. In the framework, the genomic data and phenotypic 
data are processed with GWAS or AI techniques and the genomic data affect five 
functions in prediction of diagnosis, disease risks, test, prescription and other 
events.  
Future studies will focus on implementation of each part in the framework 
and how the datasets of genomic and phenotypic sides can integrate with one 
another. Furthermore, domain knowledge of experts in medicine and 
bioinformatics is needed to evaluate the system before it comes to practical use. 
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